- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00282191
Prevalence of Spasticity in Adults With Mental Retardation Living in the Community
Prevalence of Spasticity in Adults With Mental Retardation Residing in a Community Setting
Study Overview
Status
Conditions
Detailed Description
The process of deinstitutionalization has transitioned a large majority of persons with developmental disabilities into the community over the past several decades, and that number will only increase going forward. There are 926 people in this region who are provided assistance through the Division of Mental Retardation Services (DMRS). People with developmental disabilities frequently have comorbidities such as spasticity that hinder their ability to participate in activities of daily living. Spasticity results from brain or spinal cord injury and can produce increased muscle tone, causing joint stiffness, contractures and pain that can interfere with recommended treatment. A previous survey conducted at Clover Bottom Developmental Center investigated care areas typically affected by spasticity, including splinting, hygiene, dressing, transfers, positioning, ambulation, and engaging in other functional activities. Pfister et al. reported the prevalence of spasticity in the developmental center to be 35% (72/205); of those people, the Survey Physician felt that 75% (54/72) would achieve a functional benefit from treatment.
Primary endpoints will assess the prevalence of spasticity in adults who reside in the community, and whether or not spasticity impacts activities of daily living. When appropriate, potential care area goals will be identified, and treatment options will be recorded. Secondary endpoints will examine whether or not participants currently receive treatment for spasticity; if so, what treatment is being used; and which care areas are most impacted by spasticity.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Tennessee
-
Davidson County, Tennessee, United States
- Homes
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult (18 and over) with mental retardation
- Living in a community home in Davidson County, Tennessee.
Exclusion Criteria:
None.
Study Plan
How is the study designed?
Design Details
- Observational Models: Ecologic or Community
- Time Perspectives: Cross-Sectional
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David Charles, MD, Vanderbilt University Department of Neurology
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 051220
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mental Retardation
-
Tokat Gaziosmanpasa UniversityCompletedProfound Mental Retardation
-
Hospices Civils de LyonUnknownX-linked Mental RetardationFrance
-
Ono Academic CollegeCompletedMental Retardation and Developmental Disabilities With Organic Condition
-
University of California, DavisUniversity of Alberta; St. Justine's HospitalRecruitingNeurobehavioral Manifestations | Genetic Diseases, X-Linked | Intellectual Disability | Fragile X Syndrome | Sex Chromosome Disorders | Fragile X Mental Retardation Syndrome | Trinucleotide Repeat Expansion | Fra(X) Syndrome | FXS | Mental Retardation, X LinkedUnited States, Canada
-
Instituto Politécnico de Castelo BrancoCompletedMental Retardation and Developmental Disabilities With No Organic Condition
-
Icahn School of Medicine at Mount SinaiRecruitingAutism Spectrum Disorder | DDX3X | Mental Retardation, X-linked 102United States
-
Central Hospital, Nancy, FranceCompletedGrowth Retardation
-
Tanzania Food and Drugs AuthorityUniversity Ghent; International Foundation for Science (IFS); The Nelson Mandela... and other collaboratorsCompleted
-
University of AlbertaSt. Justine's HospitalRecruitingNeurobehavioral Manifestations | Genetic Diseases, X-Linked | Mental Retardation, X-Linked | Intellectual Disability | Fragile X Syndrome | Sex Chromosome Disorders | Fragile X Mental Retardation Syndrome | Trinucleotide Repeat Expansion | Fra(X) Syndrome | FXSCanada
-
Neurogen Brain and Spine InstituteWithdrawn